PE20080065A1 - Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1 - Google Patents

Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1

Info

Publication number
PE20080065A1
PE20080065A1 PE2007000543A PE2007000543A PE20080065A1 PE 20080065 A1 PE20080065 A1 PE 20080065A1 PE 2007000543 A PE2007000543 A PE 2007000543A PE 2007000543 A PE2007000543 A PE 2007000543A PE 20080065 A1 PE20080065 A1 PE 20080065A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
benzimidazole
vainilloid
modulators
Prior art date
Application number
PE2007000543A
Other languages
English (en)
Inventor
Raul R Calvo
Scott L Dax
Michele C Jetter
William Parsons
Mark R Player
Mark A Youngman
Michael Brandt
Sharmila Patel
Jian Liu
Wing S Cheung
Yu-Kai Lee
Wenxi Pan
Kenneth M Wells
Derek A Beauchamp
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20080065A1 publication Critical patent/PE20080065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (I) DONDE LAS LINEAS PUNTEADAS ENTRE LAS POSICIONES 1, 2 Y 3 SON UN DOBLE ENLACE TAUTOMERICO; p ES 1 O 2; q ES 0 O 1; r ES DE 0 A 3; L ES ALQUILO(C1-C3), ALQUENILO(C2-C3), ALQUINILO(C2-C3) O CICLOPROPILO; A1 ES FENILO, BIFENILO, NAFTILO, INDOL, ENTRE OTROS; R1 ES OH, CN, HALOGENO, FORMILO, ALCOXI(C1-C6), ENTRE OTROS; R2 ES HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), NITRO, ENTRE OTROS; R3a Y R3b SON CADA UNO H O ALQUILO(C1-C4) OPCIONALMENTE PERFLUORADO; R4 ES HALOGENO, NITRO, CN, ALQUILO(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (E)-1-(2-{2-[2-(4-TER-BUTIL-FENIL)-VINIL]-1H-BENCIMIDAZOL-5-IL}-FENIL)-ETANONA, (E)-1-(2-{2-[2-(4-TER-BUTIL-FENIL)-VINIL]-1H-BENCIMIDAZOL-5-IL}-FENIL)-ETANOL, (E)-2-{2-[2-(4-TER-BUTIL-FENIL)-VINIL]-1H-BENCIMIDAZOL-5-IL}-FENOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR VAINILLOIDE VR1 SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR CRONICO O AGUDO
PE2007000543A 2006-05-03 2007-05-02 Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1 PE20080065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03

Publications (1)

Publication Number Publication Date
PE20080065A1 true PE20080065A1 (es) 2008-02-25

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000543A PE20080065A1 (es) 2006-05-03 2007-05-02 Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1

Country Status (37)

Country Link
US (3) US7951829B2 (es)
EP (1) EP2021330B1 (es)
JP (1) JP5302884B2 (es)
KR (1) KR101434883B1 (es)
CN (1) CN101511797B (es)
AR (1) AR060840A1 (es)
AT (1) ATE482201T1 (es)
AU (1) AU2007248341C1 (es)
BR (1) BRPI0709803B8 (es)
CA (1) CA2651128C (es)
CO (1) CO6160329A2 (es)
CR (1) CR10479A (es)
CY (1) CY1111269T1 (es)
DE (1) DE602007009378D1 (es)
DK (1) DK2021330T3 (es)
EA (1) EA019386B1 (es)
EC (1) ECSP088854A (es)
ES (1) ES2350959T3 (es)
HK (1) HK1131971A1 (es)
HR (1) HRP20100700T1 (es)
IL (1) IL194916A (es)
JO (1) JO3602B1 (es)
MX (1) MX2008014108A (es)
MY (1) MY154595A (es)
NI (1) NI200800290A (es)
NO (1) NO341965B1 (es)
NZ (1) NZ572251A (es)
PE (1) PE20080065A1 (es)
PL (1) PL2021330T3 (es)
PT (1) PT2021330E (es)
RS (1) RS51473B (es)
SI (1) SI2021330T1 (es)
TW (1) TWI419882B (es)
UA (1) UA94749C2 (es)
UY (1) UY30322A1 (es)
WO (1) WO2007130780A2 (es)
ZA (1) ZA200810234B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598485A (en) 2006-12-15 2013-08-30 Janssen Pharmaceutica Nv Benzimidazole trpv1 inhibitors
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
PE20091102A1 (es) * 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
CN101983197B (zh) * 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
JP5833745B2 (ja) 2011-05-16 2015-12-16 セルシューティクス・コーポレーション 粘膜炎の治療に使用するための化合物
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
CN105517999B (zh) * 2013-07-11 2019-06-28 百时美施贵宝公司 Ido抑制剂
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
EP3348554B1 (en) * 2015-09-08 2020-05-06 Sumitomo Chemical Company, Limited Method for producing triazole compound
EP3534888B1 (en) * 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
RS64348B1 (sr) * 2018-05-03 2023-08-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivati benzimidazola kao modulatori orfan gama receptora (rorγ) srodnih retinoida i njihova farmaceutska upotreba
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
KR20220093340A (ko) * 2019-10-31 2022-07-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 RORγ 조절제의 산부가염
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
WO2004035549A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
US7135493B2 (en) * 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
DE602004016002D1 (de) * 2003-07-28 2008-10-02 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
CN1902181A (zh) * 2003-10-28 2007-01-24 沃泰克斯药物股份有限公司 可用作离子通道调控剂的苯并咪唑
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
US8524757B2 (en) * 2006-07-04 2013-09-03 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
NZ598485A (en) * 2006-12-15 2013-08-30 Janssen Pharmaceutica Nv Benzimidazole trpv1 inhibitors

Also Published As

Publication number Publication date
CN101511797A (zh) 2009-08-19
CR10479A (es) 2009-03-31
US20070259936A1 (en) 2007-11-08
UY30322A1 (es) 2007-08-31
JP2009535414A (ja) 2009-10-01
EA200870497A1 (ru) 2009-06-30
ATE482201T1 (de) 2010-10-15
CO6160329A2 (es) 2010-05-20
NO20085031L (no) 2009-01-06
RS51473B (en) 2011-04-30
US7951829B2 (en) 2011-05-31
TW200808738A (en) 2008-02-16
ES2350959T3 (es) 2011-01-28
AU2007248341C1 (en) 2013-01-17
EP2021330B1 (en) 2010-09-22
UA94749C2 (en) 2011-06-10
AU2007248341B2 (en) 2011-12-08
WO2007130780A3 (en) 2008-02-14
BRPI0709803B8 (pt) 2021-05-25
JO3602B1 (ar) 2020-07-05
SI2021330T1 (sl) 2011-01-31
US20110190364A1 (en) 2011-08-04
ZA200810234B (en) 2010-02-24
CA2651128C (en) 2014-09-02
KR101434883B1 (ko) 2014-08-27
IL194916A (en) 2013-01-31
KR20090008428A (ko) 2009-01-21
NI200800290A (es) 2012-01-30
EP2021330A2 (en) 2009-02-11
PT2021330E (pt) 2010-12-03
BRPI0709803B1 (pt) 2019-12-10
TWI419882B (zh) 2013-12-21
WO2007130780A2 (en) 2007-11-15
HK1131971A1 (en) 2010-02-12
CA2651128A1 (en) 2007-11-15
EA019386B1 (ru) 2014-03-31
MX2008014108A (es) 2008-11-14
AR060840A1 (es) 2008-07-16
PL2021330T3 (pl) 2011-03-31
CY1111269T1 (el) 2015-08-05
MY154595A (en) 2015-06-30
ECSP088854A (es) 2008-11-27
NZ572251A (en) 2010-08-27
US20110190344A1 (en) 2011-08-04
IL194916A0 (en) 2009-08-03
CN101511797B (zh) 2013-01-02
DK2021330T3 (da) 2010-12-06
AU2007248341A1 (en) 2007-11-15
BRPI0709803A2 (pt) 2011-07-26
NO341965B1 (no) 2018-03-05
HRP20100700T1 (hr) 2011-02-28
DE602007009378D1 (de) 2010-11-04
JP5302884B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
PE20080065A1 (es) Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20141375A1 (es) Activadores de glucoquinasa
PE20081454A1 (es) Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20060079A1 (es) DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR062111A1 (es) Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
PE20091222A1 (es) Bifenilo sustituidos como moduladores del receptor gpra40
PE20091096A1 (es) Compuestos organicos
PE20081472A1 (es) Compuestos de pirazolina
PE20070016A1 (es) Compuestos heterociclicos n-enlazados como antagonistas del receptor p2y1

Legal Events

Date Code Title Description
FG Grant, registration